Flap infection associated with medicinal leeches in reconstructive surgery: two new drug-resistant organisms
Bibbo C, Fritsche T, Stemper M, Hall M (2013) · Journal of Reconstructive Microsurgery · n=2
Study Profile
- Design
- two-case report with management protocol review (Marshfield Clinic, Wisconsin)
- Sample size (n)
- 2
- Intervention
- Standard leech therapy in reconstructive surgery patients with subsequent identification of two new multidrug-resistant organisms causing flap infection
- Comparator
- Standard Aeromonas hydrophila-targeted prophylactic regimens (proven inadequate for these strains)
- Primary endpoint
- Identification of novel resistant organisms and clinical management protocol
- Primary result
- Two new multidrug-resistant organisms identified from medicinal leech therapy resulting in flap infection; suspected leech-borne infection evaluation and management protocol presented
- Follow-up duration
- Postoperative infection course
- PMID
- 23599212
Key Findings
- Two new multidrug-resistant organisms identified
- Beyond traditional Aeromonas hydrophila coverage
- Comorbidities: arthropathy, obesity (morbid)
- Management protocol for suspected leech-borne resistant infections
- Supports antibiogram-guided empiric therapy
Limitations
- Only 2 cases - cannot characterize population resistance
- Single institution experience
- Specific organisms not detailed in abstract
- Underlying comorbidities may select for resistant flora
- Cannot recommend universal protocol changes
Clinical Implications
Bibbo 2013 documents two novel multidrug-resistant organisms from medicinal leech therapy and provides clinical management protocol. For US clinicians under K040187, the case report highlights the need for individualized microbiologic evaluation in suspected leech-borne infections, particularly in patients with significant comorbidities (obesity, joint disease).
Related Trials
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)
Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)
Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)